S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Gold explodes past $2,000, here's what's next (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Gold explodes past $2,000, here's what's next (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Investing Wizard Who Turned $37K Into $2.7M in Just 4 Years Makes His Next Big Move (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:TTNP

Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis

$7.78
-0.13 (-1.64%)
(As of 02/23/2024 ET)
Today's Range
$7.57
$7.78
50-Day Range
$5.16
$8.80
52-Week Range
$5.00
$19.13
Volume
1,226 shs
Average Volume
14,892 shs
Market Capitalization
$5.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TTNP stock logo

About Titan Pharmaceuticals Stock (NASDAQ:TTNP)

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.

TTNP Stock Price History

TTNP Stock News Headlines

Titan Pharmaceuticals, Inc. (TN70.F)
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Titan Pharmaceuticals Inc TTNP
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
TTNP - Titan Pharmaceuticals, Inc.
TTNP Titan Pharmaceuticals, Inc.
Titan Pharmaceuticals Provides Shareholder Update
See More Headlines
Receive TTNP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Titan Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/30/2021
Today
2/24/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:TTNP
Employees
4
Year Founded
1992

Profitability

Net Income
$-10,210,000.00
Net Margins
-2,021.31%
Pretax Margin
-2,021.31%

Debt

Sales & Book Value

Annual Sales
$560,000.00
Book Value
$1.86 per share

Miscellaneous

Free Float
565,000
Market Cap
$5.84 million
Optionable
Optionable
Beta
1.31

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. David Elliot Lazar (Age 33)
    CEO & Principal Financial Officer
    Comp: $726.08k
  • Dr. Katherine L. Beebe-DeVarney Ph.D. (Age 63)
    President, COO & Director
    Comp: $308k














TTNP Stock Analysis - Frequently Asked Questions

How have TTNP shares performed in 2024?

Titan Pharmaceuticals' stock was trading at $8.25 at the beginning of 2024. Since then, TTNP shares have decreased by 5.7% and is now trading at $7.78.
View the best growth stocks for 2024 here
.

When is Titan Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our TTNP earnings forecast
.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) released its earnings results on Tuesday, March, 30th. The specialty pharmaceutical company reported ($17.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($26.60) by $9.40. Titan Pharmaceuticals had a negative net margin of 2,021.31% and a negative trailing twelve-month return on equity of 302.61%.

When did Titan Pharmaceuticals' stock split?

Titan Pharmaceuticals's stock reverse split on the morning of Tuesday, January 9th 2024. The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Titan Pharmaceuticals own?
Who are Titan Pharmaceuticals' major shareholders?

Titan Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TTNP) was last updated on 2/24/2024 by MarketBeat.com Staff